Aurobindo announces signing of voluntary license for Pfizer Covid19 oral treatment - nirmatrelvir

Aurobindo Pharma Limited (along with its subsidiaries together referred to as "Aurobindo") has announced the signing of sub-license agreement for a generic version of Pfizer's Covid19 oral treatment nirmatrelvir with the UN backed Medicines Patent Pool (MPP), headquartered in Geneva, for manufacturing and supplying the generic drug product to 95 countries including India. Earlier MPP signed voluntary licensing agreement with Pfizer for sub-licensing this Covid-19 treatment product to qualified generic drugmakers.

Nirmatrelvir in combination with ritonavir co-pack has received emergency use/conditional authorization for Covid-19 treatment in certain populations by USFDA, the UK Medicines and Healthcare products Regulatory Agency (UKMHRA and nearly 50 other countries).

Mr.K. Nithyananda Reddy, Vice Chairman & Managing Director, Aurobindo said," We are extremely happy to partner with Medicines Patent Pool to bring this treatment option for Covid19 to low & middle income countries. Aurobindo has already developed and commercialized ritonavir which is used as a booster along with nirmatrelvir. We are excited to work on this molecule and will soon make it available commercially at an affordable price for these markets after due process of registration and approval in various countries including DCGI in India. This combination will be a very valuable addition to our portfolio along with Molnaflu® (molnupiravir) for the treatment of Covid19."

For nirmatrelvir and ritonavir molecules, like other antivirals, Aurobindo enjoys backward integration with inhouse API manufacturing which equips it with stronger control on supply chain and cost efficiencies. The product will be manufactured at the Company's state of the art manufacturing facilities in India that are approved by global regulatory agencies including USFDA and UKMHRA. The Company has adequate capacities to meet the global demand across the 95 Countries including India.

Shares of Aurobindo Pharma Limited was last trading in BSE at Rs. 640.25 as compared to the previous close of Rs. 637.40. The total number of shares traded during the day was 53087 in over 2279 trades.

The stock hit an intraday high of Rs. 654.95 and intraday low of 637.40. The net turnover during the day was Rs. 34247864.00.

Source : Equity Bulls

Keywords

AurobindoPharma INE406A01037 SubLicenseAgreement Pfizer Covid19 OralTreatment Nirmatrelvir